IP Library Granted Patent US 9,890,129
Granted Patent B2
US 9,890,129 · App. 15/506,634 · Granted Feb 13, 2018

Aminoalkylbenzothiazepine derivatives and uses thereof

Inventors: Won-Hyuk Jung (Yongin-si, KR); Seung In Kim (Daejeon, KR); Seung Hee Ji (Seoul, KR); Dong Hyun Ko (Gwacheon-si, KR); Seog Beom Song (Suwon-si, KR); Keun Ho Lee (Seoul, KR); Hyung Jin Jun (Yongin-si, KR); Dong Kyu Kim (Yongin-si, KR); Dong Hyun Kim (Seongnam-si, KR)
Assignee: CJ HEALTHCARE CORPORATION
C07D281/10A61K31/554C07C13/24C07C13/32C07C317/06A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,890,129
App. No.
15/506,634
Granted
Feb 13, 2018
Kind
B2
Abstract

The present invention relates to a novel aminoalkylbenzothiazepine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating constipation comprising the same as an active ingredient.

Claims (62)

1. A compound represented by Formula 1 below, or a pharmaceutically acceptable salt thereof:

wherein

R 1 is hydroxy, carboxy, or hydroxysulfonyl(C 1-4 alkyl);

R 2 and R 3 are each independently hydrogen, C 1-4 alkyl, hydroxy (C 1-4 alkyl);

carbamoyl(C 1-4 alkyl), carboxy, carboxy(C 1-4 alkyl), (C 5-10 heteroaryl)(C 1-4 alkyl), or (C 5-10 aryl)(C 1-4 alkyl), or R 2 and R 3 , taken together with the respective carbon atom to which they are attached, form C 3-7 cycloalkylene;

R 4 is hydrogen or carboxy(C 1-4 alkyl);

R 5 is hydrogen, halogen, (C 1-4 alkyl)thio, (C 1-4 alkyl)amino, or di(C 1-4 alkyl)amino;

R 6 and R 7 are each independently C 1-6 alkyl;

R 8 and R 9 are each independently hydrogen, hydroxy, C 1-4 alkoxy, C 1-4 alkyl, halogen, nitro, cyano, amino, (C 1-4 alkyl)amino, di(C 1-4 alkyl)amino, acetamido, formyl, C 1-4 alkanoyl, carboxy, carbamoyl, (C 1-4 alkyl)carbamoyl, di(C 1-4 alkyl)carbamoyl, carbamoyloxy, (C 1-4 alkyl)carbamoyloxy, di(C 1-4 alkyl)carbamoyloxy, (C 1-4 alkyl)sulfonyloxy, sulfamoyloxy, (C 1-4 alkyl)sulfamoyloxy, or di(C 1-4 alkyl)sulfamoyloxy;

Q is C 5-10 aryl or C 5-10 heteroaryl; and

n is an integer of 0 to 3.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydroxy, carboxy, or hydroxysulfonyl(C 1-4 alkyl);

R 2 and R 3 are each independently hydrogen, C 1-4 alkyl, hydroxy(C 1-4 alkyl), carbamoyl(C 1-4 alkyl), carboxy, carboxy(C 1-4 alkyl), or (C 5-10 heteroaryl)(C 1-4 alkyl), or R 2 and R 3 , taken together with the respective carbon atom to which they are attached, form C 3-7 cycloalkylene;

R 4 is hydrogen or carboxy(C 1-4 alkyl);

R 5 is (C 1-4 alkyl)thio;

R 6 and R 7 are each independently C 1-6 alkyl;

R 8 and R 9 are each independently hydrogen, hydroxy, halogen, or C 1-4 alkoxy;

Q is C 5-10 aryl; and

n is an integer of 0 to 3.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is hydroxy, carboxy, or hydroxysulfonylmethyl.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 3 are each independently hydrogen, carboxy, methyl, isobutyl, carbamoylmethyl, carboxymethyl, carboxyethyl, hydroxymethyl, imidazolylmethyl, indolylmethyl, or ethyl, or R 2 and R 3 , taken together with the respective carbon atom to which they are attached, form cyclopropylene.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen, carboxymethyl, or carboxyethyl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 5 is methylthio, ethylthio, or dimethylamino.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 6 and R 7 are both butyl or both ethyl.

8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 8 and R 9 are each independently hydrogen, hydroxy, methoxy, methyl, ethyl, fluoro, chloro, nitro, cyano, amino, methylamino, ethylamino, dimethylamino, acetyl, carboxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, carbamoyloxy, methylcarbamoyloxy, dimethylcarbamoyloxy, methylsulfonyloxy, sulfamoyloxy, methylsulfamoyloxy, or dimethylsulfamoyloxy.

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Q is phenyl, pyridinyl, pyrimidinyl, or thiophenyl.

10. The compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of:

1) 2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)acetic acid;

2) 3-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)propanoic acid;

3) 2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)succinic acid;

4) (S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)propanoic acid;

5) 2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)pentanedioic acid;

6) 4-amino-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-4-oxobutanoic acid;

7) (R)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)propanoic acid;

8) 2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-2-methylpropanoic acid;

9) (R)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-3-(1H-imidazol-4-yl)propanoic acid;

10) (R)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-3-(1H-indol-2-yl)propanoic acid;

11) (S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-4-methylpentanoic acid;

12) (S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)pentanedioic acid;

13) (S)-2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-3-hydroxypropanoic acid;

14) 3-((carboxymethyl)((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)propanoic acid;

15) 3-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)pentanedioic acid;

16) 2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-2-oxoacetic acid;

17) 1-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)cyclopropanecarboxylic acid;

18) 2-(((3,3-dibutyl-7-methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-2-oxoethanesulfonic acid;

19) 2-4(3,3-dibutyl-5-(4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)acetic acid;

20) 2-(((3,3-dibutyl-5-(4-hydroxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)acetic acid;

21) 2-(((3,3-dibutyl-5-(3-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)acetic acid;

22) 2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)acetic acid;

23) 2-(((3,3-dibutyl-5-(3-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)acetic acid;

24) 2-(((3,3-dibutyl-5-(3-fluoro-4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)acetic acid;

25) 2-(((3,3-dibutyl-5-(4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-2-oxoethanesulfonic acid;

26) 1-(((3,3-dibutyl-5-(3-fluoro-4-methoxyphenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)cyclopropanecarboxylic acid;

27) 2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-2-oxoacetic acid;

28) (S)-2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)propanoic acid;

29) (S)-2-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)-3-hydroxypropanoic acid; and

30) 1-(((3,3-dibutyl-5-(4-fluorophenyl)-7-methylthio-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine-8-yl)methyl)amino)cyclopropanecarboxylic acid.

11. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound according to claim 10 or a pharmaceutically acceptable salt thereof.

13. A method for treating constipation in a subject in need thereof, the method comprising administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof to the subject, thereby treating constipation.

14. A method for treating constipation in a subject in need thereof, the method comprising administering an effective amount of the compound according to claim 10 or a pharmaceutically acceptable salt thereof to the subject, thereby treating constipation.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY'S ADDRESS PREVIOUSLY RECORDED ON REEL 053193 FRAME 0392. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jul 30, 2020
From: CJ HEALTHCARE CORPORATION
To: HK INNO.N CORPORATION
Reel/Frame 053365/0859 →
CHANGE OF NAME Recorded Jul 13, 2020
From: CJ HEALTHCARE CORPORATION
To: HK INNO.N CORPORATION
Reel/Frame 053193/0392 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: JUNG, WON HYUK; KIM, SEUNG IN; JI, SEUNG HEE; KO, DONG HYUN; SONG, SEOG BEOM; LEE, KEUN HO; JUN, HYUNG JIN; KIM, DONG KYU; KIM, DONG HYUN
To: CJ HEALTHCARE CORPORATION
Reel/Frame 041888/0574 →
Priority Claims (2)
KR 10-2014-0141869 · Oct 20, 2014 · national
KR 10-2015-0069949 · May 19, 2015 · national
Continuity (1)
Related Publication 20170283386A1 · Oct 5, 2017